KR102823683B1 - 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제 - Google Patents

항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제 Download PDF

Info

Publication number
KR102823683B1
KR102823683B1 KR1020187001434A KR20187001434A KR102823683B1 KR 102823683 B1 KR102823683 B1 KR 102823683B1 KR 1020187001434 A KR1020187001434 A KR 1020187001434A KR 20187001434 A KR20187001434 A KR 20187001434A KR 102823683 B1 KR102823683 B1 KR 102823683B1
Authority
KR
South Korea
Prior art keywords
delete delete
antibody
cells
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187001434A
Other languages
English (en)
Korean (ko)
Other versions
KR20180025897A (ko
Inventor
아키히로 도쿠나가
도시히코 이시이
모토야 미에
무네토시 안도
Original Assignee
쿄와 기린 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿄와 기린 가부시키가이샤 filed Critical 쿄와 기린 가부시키가이샤
Publication of KR20180025897A publication Critical patent/KR20180025897A/ko
Application granted granted Critical
Publication of KR102823683B1 publication Critical patent/KR102823683B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187001434A 2015-07-14 2016-07-14 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제 Active KR102823683B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192173P 2015-07-14 2015-07-14
US62/192,173 2015-07-14
PCT/JP2016/003337 WO2017010106A1 (en) 2015-07-14 2016-07-14 A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody

Publications (2)

Publication Number Publication Date
KR20180025897A KR20180025897A (ko) 2018-03-09
KR102823683B1 true KR102823683B1 (ko) 2025-06-23

Family

ID=57757291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001434A Active KR102823683B1 (ko) 2015-07-14 2016-07-14 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제

Country Status (10)

Country Link
US (2) US20180271861A1 (https=)
EP (2) EP3322444A4 (https=)
JP (2) JP2018524361A (https=)
KR (1) KR102823683B1 (https=)
CN (1) CN107847597A (https=)
AU (1) AU2016293667A1 (https=)
CA (1) CA2992238A1 (https=)
HK (1) HK1252514A1 (https=)
TW (1) TW201713332A (https=)
WO (1) WO2017010106A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4039274A1 (en) 2017-07-28 2022-08-10 Phanes Therapeutics, Inc. Anti-tim-3 antibodies and uses thereof
KR102817790B1 (ko) * 2018-08-29 2025-06-05 케모센트릭스, 인크. C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065905A1 (en) * 2010-05-10 2013-03-14 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
WO2014186035A1 (en) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677A (en) 1848-07-25 Improvement in hillside-plows
US603A (en) 1838-02-15 Improvement in the construction of many-chambered fire-arms
US4968A (en) 1847-02-13 Spinal elevator
US171A (en) 1837-04-20 Machine for washing iron and other ores
US337A (en) 1837-07-31 Mode of constructing railroad-frogs
US5821A (en) 1848-10-03 Cream-freezer
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
WO2005057341A2 (en) 2003-12-02 2005-06-23 Koolspan, Inc. Automatic hardware-enabled virtual private network system
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2682382A1 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
JP5465720B2 (ja) * 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
US8673908B2 (en) 2008-11-10 2014-03-18 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
WO2011042065A1 (en) 2009-10-09 2011-04-14 Daniel Monsch "momoheli" lifting module and vehicles
AU2011262758B8 (en) * 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
EP3312173B1 (en) 2011-11-09 2021-12-22 Kyowa Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US9207238B2 (en) * 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
ES2799582T3 (es) * 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
WO2015186823A1 (ja) 2014-06-06 2015-12-10 協和発酵キリン株式会社 Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065905A1 (en) * 2010-05-10 2013-03-14 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
WO2014186035A1 (en) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway

Also Published As

Publication number Publication date
EP3991749A3 (en) 2022-08-24
WO2017010106A1 (en) 2017-01-19
CN107847597A (zh) 2018-03-27
EP3322444A4 (en) 2019-06-12
TW201713332A (zh) 2017-04-16
EP3322444A1 (en) 2018-05-23
JP2018524361A (ja) 2018-08-30
KR20180025897A (ko) 2018-03-09
US20220088011A1 (en) 2022-03-24
AU2016293667A1 (en) 2018-01-04
CA2992238A1 (en) 2017-01-19
US20180271861A1 (en) 2018-09-27
JP7366093B2 (ja) 2023-10-20
EP3991749A2 (en) 2022-05-04
HK1252514A1 (zh) 2019-05-31
JP2021191780A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
JP7366093B2 (ja) 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤
Flieswasser et al. The CD70-CD27 axis in oncology: the new kids on the block
Yun et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC
CN106459184B (zh) 与抗cd38抗体联用的组合疗法
TWI680985B (zh) 抗ｏｘ-４０抗體及使用方法
JP2024153659A (ja) 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
JP2017503001A (ja) がんを処置するための療法
KR20250053841A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN106132439A (zh) 包含抗血管发生剂和ox40结合激动剂的组合疗法
EP2601220A2 (en) Use of her3 binding agents in prostate treatment
JP2023539589A (ja) Ｅｇｆｒ変異を有する非小細胞肺がんの治療
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
KR20230061421A (ko) Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법
WO2021084124A1 (en) COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
JP2023511277A (ja) Ｃｃｒ５陽性の転移性のがんの処置のためのｃｃｒ５結合剤
KR20250052369A (ko) 암의 치료 및/또는 예방을 위한 의약품
TW202416995A (zh) 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
EA053157B1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ И СТРАТИФИКАЦИЯ ПАЦИЕНТОВ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К РЕЦЕПТОРАМ EGFR И c-MET
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2
NISHIBATA Studies on Molecular Targeted Agents as Candidates of Combination Partner for Cancer Immunotherapy
BR122024010998A2 (pt) Uso de um anticorpo anti-cd38

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210713

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241028

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250321

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250618

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250618

End annual number: 3

Start annual number: 1

PG1601 Publication of registration